Early encapsulation of peripancreatic fluid/necrosis collections on imaging (CECT) in acute pancreatitis : influential factors and clinical significance for prognosis
© 2024. The Author(s)..
BACKGROUND: To identify the factors influencing the early encapsulation of peripancreatic fluid/necrosis collections via contrast-enhanced computed tomography (CECT) and to determine the clinical significance of early encapsulation for determining the prognosis of acute pancreatitis (AP) patients.
METHODS: AP patients who underwent CECT between 4 and 10 days after disease onset were enrolled in this study. Early encapsulation was defined as a continuous enhancing wall around peripancreatic fluid/necrosis collections on CECT. Univariate and multivariate logistic regression analyses were performed to assess the associations between the variables and early encapsulation. Clinical outcomes were compared between the non-encapsulation and early encapsulation groups with 1:1 propensity score matching.
RESULTS: A total of 289 AP patients were enrolled. The intra-observer and inter-observer agreement were considered good (kappa statistics of 0.729 and 0.614, respectively) for identifying early encapsulation on CECT. The ratio of encapsulation increased with time, with a ratio of 12.5% on day 5 to 48.7% on day 9. Multivariate logistic regression analysis revealed that the longer time from onset to CECT examination (OR 1.55, 95% CI 1.23-1.97), high alanine aminotransferase level (OR 0.98, 95% CI 0.97-0.99), and high APACHE II score (OR 0.89, 95% CI 0.81-0.98) were found to be independent factors associated with delayed encapsulation. The incidence of persistent organ failure was significantly lower in the early encapsulation group after matching (22.4% vs 6.1%, p = 0.043). However, there was no difference in the incidence of infected pancreatic necrosis, surgical intervention, or in-hospital mortality.
CONCLUSIONS: AP patients without early encapsulation of peripancreatic fluid/necrosis collections have a greater risk of persistent organ failure. In addition to longer time, the high APACHE II score and elevated alanine aminotransferase level are factors associated with delayed encapsulation.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
BMC gastroenterology - 24(2024), 1 vom: 29. Jan., Seite 53 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ning, Ning [VerfasserIn] |
---|
Links: |
---|
Themen: |
Acute pancreatitis |
---|
Anmerkungen: |
Date Completed 31.01.2024 Date Revised 01.02.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s12876-024-03145-7 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM367775751 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM367775751 | ||
003 | DE-627 | ||
005 | 20240201232229.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240130s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12876-024-03145-7 |2 doi | |
028 | 5 | 2 | |a pubmed24n1277.xml |
035 | |a (DE-627)NLM367775751 | ||
035 | |a (NLM)38287237 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ning, Ning |e verfasserin |4 aut | |
245 | 1 | 0 | |a Early encapsulation of peripancreatic fluid/necrosis collections on imaging (CECT) in acute pancreatitis |b influential factors and clinical significance for prognosis |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 31.01.2024 | ||
500 | |a Date Revised 01.02.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s). | ||
520 | |a BACKGROUND: To identify the factors influencing the early encapsulation of peripancreatic fluid/necrosis collections via contrast-enhanced computed tomography (CECT) and to determine the clinical significance of early encapsulation for determining the prognosis of acute pancreatitis (AP) patients | ||
520 | |a METHODS: AP patients who underwent CECT between 4 and 10 days after disease onset were enrolled in this study. Early encapsulation was defined as a continuous enhancing wall around peripancreatic fluid/necrosis collections on CECT. Univariate and multivariate logistic regression analyses were performed to assess the associations between the variables and early encapsulation. Clinical outcomes were compared between the non-encapsulation and early encapsulation groups with 1:1 propensity score matching | ||
520 | |a RESULTS: A total of 289 AP patients were enrolled. The intra-observer and inter-observer agreement were considered good (kappa statistics of 0.729 and 0.614, respectively) for identifying early encapsulation on CECT. The ratio of encapsulation increased with time, with a ratio of 12.5% on day 5 to 48.7% on day 9. Multivariate logistic regression analysis revealed that the longer time from onset to CECT examination (OR 1.55, 95% CI 1.23-1.97), high alanine aminotransferase level (OR 0.98, 95% CI 0.97-0.99), and high APACHE II score (OR 0.89, 95% CI 0.81-0.98) were found to be independent factors associated with delayed encapsulation. The incidence of persistent organ failure was significantly lower in the early encapsulation group after matching (22.4% vs 6.1%, p = 0.043). However, there was no difference in the incidence of infected pancreatic necrosis, surgical intervention, or in-hospital mortality | ||
520 | |a CONCLUSIONS: AP patients without early encapsulation of peripancreatic fluid/necrosis collections have a greater risk of persistent organ failure. In addition to longer time, the high APACHE II score and elevated alanine aminotransferase level are factors associated with delayed encapsulation | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Acute pancreatitis | |
650 | 4 | |a Contrast-enhanced computed tomography | |
650 | 4 | |a Infection | |
650 | 4 | |a Organ failure | |
650 | 4 | |a Risk factors | |
650 | 7 | |a Alanine Transaminase |2 NLM | |
650 | 7 | |a EC 2.6.1.2 |2 NLM | |
700 | 1 | |a Yu, Congyi |e verfasserin |4 aut | |
700 | 1 | |a Sun, Wenwu |e verfasserin |4 aut | |
700 | 1 | |a Wen, Yi |e verfasserin |4 aut | |
700 | 1 | |a Ni, Tongtian |e verfasserin |4 aut | |
700 | 1 | |a Sheng, Huiqiu |e verfasserin |4 aut | |
700 | 1 | |a Chen, Ying |e verfasserin |4 aut | |
700 | 1 | |a Ma, Li |e verfasserin |4 aut | |
700 | 1 | |a Chen, Erzhen |e verfasserin |4 aut | |
700 | 1 | |a Zhao, Bing |e verfasserin |4 aut | |
700 | 1 | |a Mao, Enqiang |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC gastroenterology |d 2001 |g 24(2024), 1 vom: 29. Jan., Seite 53 |w (DE-627)NLM110904761 |x 1471-230X |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:29 |g month:01 |g pages:53 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12876-024-03145-7 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 24 |j 2024 |e 1 |b 29 |c 01 |h 53 |